Consumer doubt over TGA agenda
The Therapeutic Goods Administration (TGA) has come under fire from consumers who argue the regulatory body’s operations suggest it represents the interests of the therapeutics industry and not consumers.
In a submission to an ongoing review into the transparency of the TGA’s operations, the Consumers Health Forum of Australia (CHF) has claimed that the TGA’s funding, sourced entirely from drug manufacturers, presents a potential conflict of interest for the regulator.
Carol Bennett, chief executive officer of the CHF, said government funding was needed to ensure any conflict of interest was negated.
“Ideally there would be, as there is in other countries, some level of government [financial] contribution to activities such as adverse event reporting, where there may be an otherwise perceived conflict,” she told Medical Observer.
A lack of consumer engagement regarding adverse event reporting compounded